Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linerixibat and Obeticholic Acid DDI Study
NCT05133830Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linerixibat in cholestatic pruritus (4 arms), sponsored by GSK. Primary endpoint: Average trough concentration in plasma for total-OCA at steady state. Started Nov 2021; status: completed.
02
Drugs
linerixibat
03
Conditions
cholestatic pruritus
Beyond the preview
Go deeper on NCT05133830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133830.